{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:32:25Z","timestamp":1788280345622,"version":"build-2803163510"},"reference-count":21,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"vor","delay-in-days":1073,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Medicine"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.7861\/clinmed.2021-0280","type":"journal-article","created":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T16:55:31Z","timestamp":1621270531000},"page":"177-181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Advances in atopic dermatitis"],"prefix":"10.1016","volume":"21","author":[{"given":"Alice","family":"Plant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R","family":"Ardern-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.7861\/clinmed.2021-0280_bib1","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1365-2133.1994.tb08532.x","article-title":"The UK working party's diagnostic criteria for atopic dermatitis","volume":"131","author":"Williams","year":"1994","journal-title":"Br J Dermatol"},{"key":"10.7861\/clinmed.2021-0280_bib2","series-title":"Dermatology: an illustrated colour text","author":"Gawkrodger","year":"2017"},{"key":"10.7861\/clinmed.2021-0280_bib3","doi-asserted-by":"crossref","first-page":"66","DOI":"10.7861\/clinmedicine.16-1-66","article-title":"Atopic eczema","volume":"16","author":"Brown","year":"2016","journal-title":"Clin Med"},{"key":"10.7861\/clinmed.2021-0280_bib4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jdin.2020.10.002","article-title":"The global, regional, and national burden of atopic dermatitis in 195 countries and territories: an ecological study from the Global Burden of Disease Study 2017","volume":"2","author":"Urban","year":"2021","journal-title":"JAAD international"},{"key":"10.7861\/clinmed.2021-0280_bib5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaip.2019.06.044","article-title":"Update on atopic dermatitis: diagnosis, severity assessment and treatment selection","volume":"8","author":"Fishbein","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.7861\/clinmed.2021-0280_bib6","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/jid.2011.393","article-title":"One remarkable molecule: filaggrin","volume":"132","author":"Brown","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.7861\/clinmed.2021-0280_bib7","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1038\/jid.2013.148","article-title":"Sensitization via healthy skin programs Th2 responses in individuals with atopic dermatitis","volume":"133","author":"Newell","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.7861\/clinmed.2021-0280_bib8","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1038\/jid.2013.446","article-title":"The Global Burden of Skin Disease in 2010: an analysis of the prevalence and impact of skin conditions","volume":"134","author":"Hay","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.7861\/clinmed.2021-0280_bib9","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","article-title":"Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study","volume":"121","author":"Silverberg","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.7861\/clinmed.2021-0280_bib10","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jaci.2012.10.041","article-title":"Mental health comorbidity in patients with atopic dermatitis","volume":"131","author":"Aghmaie","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.7861\/clinmed.2021-0280_bib11","author":"National Institute for Health and Care Excellence","year":"2018","journal-title":"Dupilumab for treating moderate to severe atopic dermatitis: Technology appraisal guidance [TA534]"},{"key":"10.7861\/clinmed.2021-0280_bib12","unstructured":"National Institute for Health Research. Dupilumab for children aged 12 years to 17 years with moderate to severe atopic dermatitis: NIHRIO (HSRIC) ID: 20586; NICE ID 9830. NIHR, 2018."},{"key":"10.7861\/clinmed.2021-0280_bib13","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmed.2021-0280_bib14","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jaad.2020.09.084","article-title":"Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: A propensity score\u2013matched cohort study","volume":"84","author":"Schneeweiss","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.7861\/clinmed.2021-0280_bib15","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.idc.2020.02.003","article-title":"Infectious implications of interleukin-1, interleukin-6, and T Helper type 2 inhibition","volume":"34","author":"Liu","year":"2020","journal-title":"Infect Dis Clin North Am"},{"key":"10.7861\/clinmed.2021-0280_bib16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.anai.2020.05.028","article-title":"New and emerging treatments for inflammatory itch","volume":"126","author":"Erickson","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.7861\/clinmed.2021-0280_bib17","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s40257-020-00548-6","article-title":"Selective JAK1 inhibitors for the treatment of atopic dermatitis: focus on upadacitinib and abrocitinib","volume":"21","author":"Ferreria","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"10.7861\/clinmed.2021-0280_bib18","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","article-title":"Efficacy and Safety of Abrocitinib in patients with moderate-to-severe atopic dermatitis, a randomized clinical trial","volume":"156","author":"Silverberg","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.7861\/clinmed.2021-0280_bib19","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jaci.2019.11.025","article-title":"Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial","volume":"145","author":"Guttman-Yassky","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.7861\/clinmed.2021-0280_bib20","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/jamadermatol.2020.3260","article-title":"Efficacy and safety of baracitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis, a randomized clinical trial","volume":"156","author":"Reich","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.7861\/clinmed.2021-0280_bib21","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/bjd.17755","article-title":"Nasal and skin microbiomes are associated with disease severity in paediatric atopic dermatitis","volume":"181","author":"Totte","year":"2019","journal-title":"Br J Dermatol"}],"container-title":["Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211824031294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211824031294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.7861\/clinmed.2021-0280","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T08:48:43Z","timestamp":1744447723000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470211824031294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S1470211824031294"],"URL":"https:\/\/doi.org\/10.7861\/clinmed.2021-0280","relation":{},"ISSN":["1470-2118"],"issn-type":[{"value":"1470-2118","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in atopic dermatitis","name":"articletitle","label":"Article Title"},{"value":"Clinical Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.7861\/clinmed.2021-0280","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 Royal College of Physicians 2021. All rights reserved.","name":"copyright","label":"Copyright"}]}}